Microbot Medical Secured First Customer in California

The company accelerated its commercial growth strategy for its FDA-cleared robotic vascular system.

Updated on Sept. 25, 2026 in Robotics

Bold vector editorial illustration showing a surgical catheter guide and robotic control arm, representing medical technology adoption. — Microbot Medical has secured its first California customer for its LIBERTY robotic system, marking a key expansion in its effort to scale endovascular surgery technology. AI Illustration. Upload story photo >

Live Poll

Do you trust that new medical robotics technologies are being safely and reliably integrated into hospitals?

Microbot Medical has secured its first customer in California and expanded its sales presence in North Carolina. This commercial development follows the company's recent analyst meeting outlining plans to accelerate adoption of its FDA-cleared LIBERTY System.

Why it matters

The company aims to scale its reach across multi-hospital healthcare systems by expanding its sales force and manufacturing capacity. This strategy is designed to drive adoption of the LIBERTY System in peripheral endovascular procedures.

The LIBERTY System is a remotely operated, single-use robotic platform cleared by the FDA for peripheral endovascular procedures. To scale production, the company has added a second manufacturing line to improve operating efficiencies.

The players

Microbot Medical

A Hingham, Massachusetts-based medical technology firm focused on developing robotic systems for endovascular surgical procedures.

The details

The LIBERTY System utilizes a remotely operated robotic interface to perform peripheral endovascular procedures—minimally invasive surgeries on blood vessels outside of the heart. Microbot Medical is currently navigating the Value Analysis Committee process, a 4-to-6-month institutional review cycle used by hospitals to evaluate the clinical and financial utility of new medical technologies before purchase.

September 24, 2026: The company held an analyst meeting in New York City.
End of 2026: The company aims to reach a total of 12 sales territories.
Late Q4 2026 or early Q1 2027: Expected timeline for CE mark approval.
2027: The company expects to reach positive gross margins.

The Tech Race

Microbot Medical is attempting to secure a footprint in the competitive endovascular robotics field by scaling its sales infrastructure. This growth strategy positions the company against existing robotic surgery platforms while it works toward obtaining its CE mark for international market entry.

Healthcare providers in the United States will see increased availability of the LIBERTY System as the company adds new sales territories through late 2026. The move toward larger multi-hospital deployments suggests that patient access to this robotic procedure will scale as institutional vetting committees complete their evaluation periods.

The takeaway

Microbot Medical is shifting its focus from product clearance to rapid commercial scaling in the United States. Observers should track the company's progress toward its goal of positive gross margins in 2027 as a key indicator of successful market adoption.